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Abstract
Influenza viruses undergo continual antigenic evolution allowing mutant viruses
to evade host immunity acquired to previous virus strains. Antigenic phenotype is
often assessed through pairwise measurement of cross-reactivity between influenza
strains using the hemagglutination inhibition (HI) assay. Here, we extend previous
approaches to antigenic cartography, and simultaneously characterize antigenic and
genetic evolution by modeling the diffusion of antigenic phenotype over a shared virus
phylogeny. Using HI data from influenza lineages A/H3N2, A/H1N1, B/Victoria and
B/Yamagata, we determine patterns of antigenic drift across viral lineages, showing
that A/H3N2 evolves faster and in a more punctuated fashion than other influenza
lineages. We also show that year-to-year antigenic drift appears to drive incidence
patterns within each influenza lineage. This work makes possible substantial future
advances in investigating the dynamics of influenza and other antigenically-variable
pathogens by providing a model that intimately combines molecular and antigenic
evolution.
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Introduction
Seasonal influenza infects between 10% and 20% of the human population every year,
causing an estimated 250,000 to 500,000 deaths annually [1]. While individuals develop
long-lasting immunity to particular influenza strains after infection, antigenic mutations to
the influenza virus genome result in proteins that are recognized to a lesser degree by the
human immune system, leaving individuals susceptible to future infection. The influenza
virus population continually evolves in antigenic phenotype in a process known as antigenic
drift. A large proportion of the disease burden of influenza stems from antigenic drift,
which allows individuals to be infected multiple times throughout their lives. Although
influenza vaccines may lack efficacy for a variety of reasons [2], antigenic drift causes
efficacy of a fixed vaccine formulation against circulating viruses to decline over time. A
thorough understanding of the process of antigenic drift is essential to public health efforts
to control mortality and morbidity through the use of a seasonal influenza vaccine.
Before 2009, there were four major lineages of influenza circulating within the human
population: the H3N2 and H1N1 subtypes of influenza A, and the Victoria and Yamagata
lineages of influenza B. In the case of influenza A, subtypes A/H3N2 and A/H1N1 refer
to the genes, hemagglutinin (H or HA) and neuraminidase (N or NA), that are primarily
responsible for the antigenic character of a strain. In the case of influenza B, Victoria
(B/Vic) and Yamagata (B/Yam) refer to antigenically distinct lineages which diverged
from a single lineage prior to 1980 [3]. Mutations to the HA1 region of the hemagglutinin
protein are thought to drive the majority of antigenic drift in the influenza virus [4, 5].
Experimental characterization of antigenic phenotype is possible through the hemaggluti-
nation inhibition (HI) assay [6], which measures the cross-reactivity of one virus strain to
serum raised against another strain through challenge or vaccination. Sera raised against
older strains react poorly to more recent viruses resulting in new strains having a selective
advantage over previously established strains.
The results of many HI assays across a multitude of viruses of a single subtype can be
combined to yield a two-dimensional map, quantifying antigenic similarity and distance [7].
The antigenic map of influenza A/H3N2 has shown substantial evolution of the influenza
virus population since its emergence in 1968. Evolution of antigenic phenotype appears
punctuated with episodes of more rapid innovation interspersed by periods of relative
stasis, while genetic evolution appears more continuous [7], suggesting that a relatively
small number of genetic changes or combinations of genetic changes may drive changes
in antigenic phenotype [8]. The process of antigenic drift results in the rapid turnover of
the virus population, so that despite mutation, genetic diversity among contemporaneous
viruses remains low. Such population turnover is supported by phylogenetic analysis
that shows a characteristically ‘spindly’ tree with a single predominant trunk lineage and
transitory side branches that persist for only 1–5 years [9].
Previously, the antigenic and genetic patterns of influenza evolution have been analyzed
essentially in isolation. An antigenic map is constructed from a panel of HI measurements,
and a phylogenetic tree is constructed from sequence data. However, the opportunity for
a combined approach exists as both the antigenic map and the phylogenetic tree often
contain many of the same isolates. Here, we implement a flexible Bayesian approach to
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jointly characterize the antigenic and genetic evolution of the influenza virus population.
We apply this approach to investigate the dynamics of A/H3N2, A/H1N1, B/Vic and
B/Yam viruses, and, for the first time, present detailed reconstructions of the antigenic
dynamics of all four circulating influenza lineages.
Results and discussion
Antigenic and evolutionary cartography
In order to assess patterns of antigenic evolution among influenza strains, we imple-
mented a Bayesian probabilistic analog of multidimensional scaling (MDS), referred to
here as BMDS (see Materials and methods). In this model, viruses and sera are given
N -dimensional locations, thus specifying an ‘antigenic map’, such that distances between
viruses and sera in this space are inversely proportional to cross-reactivity. In the BMDS
model, a map distance of one antigenic unit translates to an expectation of a 2-fold drop
in HI titer between virus and sera. Maps that produce pairwise distances most congruent
with the observed titers will have a high likelihood and will be favored by the BMDS
model. We integrate over sources of uncertainty, such as antigenic locations, in a flexi-
ble Bayesian fashion. We apply this model to HI measurements of virus isolates against
post-infection ferret antisera for influenza A/H3N2, A/H1N1, B/Vic and B/Yam.
We begin with Bayesian analogs of the models used by Smith et al. [7], in which viruses and
sera are represented as N -dimensional locations as described in the ‘Antigenic cartography’
section of Materials and methods. In this case, ‘serum potencies’ are fixed to the maximum
titers exhibited by particular ferret sera and give the baseline expectation for titer when
virus and serum are antigenically identical. Potency differs between serum isolates due to
experimental noise (e.g. variation in serum concentration), but also due to differential ferret
immune responses, causing some serum isolates to inhibit hemagglutination at generally
higher titers than other isolates. In this model, virus and serum locations follow an
uninformative diffuse normal prior. After comparing models of differing dimensions, Smith
et al. [7] arrive at a 2D model as the preferred model for their data. Smith et al. [7]
implement a form of MDS, seeking to optimize virus and serum locations such that the sum
of squared errors between expected and observed titers is minimized (eq. 3 of Materials
and methods). Here, in implementing BMDS, we provide a likelihood function for the
probability of observing HI data given virus and serum locations (eq. 8 of Materials and
methods) and seek to estimate model parameters through Bayesian inference using Markov
chain Monte Carlo (MCMC). However, the basic antigenic model describing drop in HI
titer as proportional to Euclidean distance between virus and serum locations is identical
between these methods.
We test model performance by constructing training datasets representing 90% of the HI
measurements for each of the four influenza lineages and test datasets representing the
remaining 10% of the measurements for each lineage. By fitting the BMDS model to
the training dataset, we are able to predict HI titers in the test dataset and compare
these predicted titers to observed titers. We find that a two dimensional model has better
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predictive power than models of lower or higher dimension in all four influenza lineages
(models 1–5; Table 1). We find that this 2D model performs well, yielding an average
absolute predictive error of between 0.78 and 0.91 log2 HI titers across influenza lineages
(model 2; Table 1), in line with the results of Smith et al. [7]. Consequently, we specify
a two dimensional model in all subsequent analyses. The finding of a low-dimensional
map across influenza lineages extends previous studies in A/H3N2 [7] and remains an
interesting and fundamental empirical observation.
Table 1. Average absolute prediction error of log2 HI titer for test data across models
and datasets.
Test error
Model Data Dimen Location prior Serum potency Virus avidity A/H3N2 A/H1N1 B/Vic B/Yam
1 HI 1D Uninformed Fixed None 1.35 0.94 0.90 1.08
2 HI 2D Uninformed Fixed None 0.91 0.78 0.82 0.90
3 HI 3D Uninformed Fixed None 0.93 0.80 0.85 0.92
4 HI 4D Uninformed Fixed None 0.98 0.84 0.90 0.97
5 HI 5D Uninformed Fixed None 1.04 0.89 0.98 1.04
6 HI/year 2D Drift Fixed None 0.91 0.75 0.77 0.83
7 HI/year/seq 2D Diffusion/Drift Fixed None 0.89 0.74 0.74 0.83
8 HI/year/seq 2D Diffusion/Drift Estimated None 0.77 0.73 0.66 0.75
9 HI/year/seq 2D Diffusion/Drift Fixed Estimated 0.80 0.72 0.69 0.75
10 HI/year/seq 2D Diffusion/Drift Estimated Estimated 0.76 0.71 0.64 0.72
Previous work on influenza antigenic and genetic evolution has shown that antigenic dis-
tance accumulates with increasing genetic distance [7, 10, 11]. Here, we examine pairwise
relationships between viruses and observe a correlation between amino acid mutations
and antigenic distance (Figure 1) and a similar correlation between phylogenetic distance,
measured in years, and antigenic distance (Figure 1). Thus, genetic relationships between
viruses provide some predictive power to estimate antigenic distances in the absence of HI
data. However, the magnitudes of the coefficients of determination R2 are low (Figure 1),
suggesting that genetic relationships alone will not completely resolve antigenic distances.
Consequently, we seek to flexibly incorporate genetic data by modeling antigenic pheno-
type as an evolutionary diffusion [12], wherein a virus’s antigenic character state evolves
along branches of the phylogenetic tree according to a Brownian motion process (see Mate-
rials and methods). The phylogenetic diffusion process acts as a prior on virus locations, so
that genetically similar viruses are expected to share similar antigenic locations. The anti-
genic diffusion process includes both systematic drift with time and covariance induced by
phylogenetic proximity. We examine the effects of including only systematic drift (model
6; Table 1) and systematic drift plus phylogenetic diffusion (model 7; Table 1), finding a
small increase in predictive accuracy of between 0.02 and 0.08 log2 HI titers when both
processes are included. The systematic drift process informs virus and serum locations by
dates of isolation and the phylogenetic diffusion process informs virus locations by genetic
sequences. Thus, in these models, antigenic locations are inferred using both genetic data
and HI data and will differ from locations inferred from HI data alone. If HI data is rich,
then we expect minor differences in antigenic locations with the inclusion of genetic data
(as may be the case for A/H3N2), while if HI data is spare, then we expect genetic data
to play a larger role in determining antigenic locations (as may be the case for B/Vic and
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Figure 1. Pairwise correlations between genetic distance, measured as amino acid
mutations or as phylogenetic distance, and antigenic distance for influenza A/H3N2,
A/H1N1, B/Vic and B/Yam. The top row shows correlations between number of amino acid
mutations in HA1 and average antigenic distance between 10,000 random pairs of viruses. The
bottom row shows correlations between average phylogenetic distance, measured in terms of years,
and average antigenic distance between 10,000 random pairs of viruses. Dashed lines show linear
model fits, with R2 and slope noted, while solid lines show LOESS fits. Antigenic distances derive
from model 2 of Table 1.
B/Yam).
We further extend the model by estimating serum potencies, rather than fixing serum
potencies at maximum titers. Serum potencies differ across isolates due to experimental
variation in serum extraction and processing or due to variation in ferret immune response.
Serum potency determines the baseline expectation of titer when virus and serum have
identical antigenic locations. However, if serum potency is fixed to the serum’s maximum
titer, this will often not be the case, as the virus giving the maximum titer may be
antigenically distinct from the serum. Thus, fixing serum potencies will tend to under-
estimate effect size; we observe a mean effect of 10.42 log2 HI titers for A/H3N2 when
fixing serum potencies and a mean of 10.94 when estimating serum potencies. We find
that estimating serum potencies improves test error further (model 8, Table 1), with
improvements of between 0.01 and 0.12 log2 HI titers.
Additionally, we include and estimate ‘virus avidity’ in an analogous fashion, which is
intended to represent differences in overall HI reactivity between viruses. Experimental
work has demonstrated that influenza variants exist that differ in HA binding activity
for cell surface glycan receptors, and that these high-avidity variants may arise in the
presence of antibody pressure [13]. The presence of differential virus avidity has been
previously shown to distort antigenic maps constructed from a model that disregards
avidity effects [14]. Here, with virus avidities estimated, baseline titer derives from both
the virus and the serum used in the HI reaction. We find that including virus avidities
further improves test error, either with fixed serum potencies (model 9, Table 1) or with
estimated serum potencies (model 10, Table 1). With fixed serum potencies, the inclusion
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of virus avidities results in improvements of between 0.02 and 0.09 log2 HI titers and
with estimated serum potencies, the inclusion of virus avidities results in improvements
of between 0.01 and 0.05 log2 HI titers.
We find that the average absolute error in predicted log2 HI titer is nearly constant with
antigenic distance (Pearson correlation, r = 0.098), thus supporting our model assumption
that the drop in log2 titer is proportional to the Euclidean distance separating viruses and
sera on the antigenic map. Additionally, we find that the absolute error in predicted titer is
nearly constant with time (Pearson correlation, r = −0.007). Antigenic locations inferred
by the model are well resolved; estimates of antigenic distance between pairs of viruses
show relatively little variation across the posterior. We estimate that virus distances have,
on average, a 50% credible interval of ±0.45 antigenic units for A/H3N2, ±0.57 units for
A/H1N1, ±0.76 units for B/Vic, and ±0.65 units for B/Yam.
We find strong correspondence between our results and previous results by Smith et
al. [7], with equivalent models producing globally consistent antigenic maps and other
models producing locally consistent maps with a small degree of global inconsistency (Fig-
ures 10–13). When implementing the same underlying model, differences in the MDS and
BMDS approaches reflect greater philosophical differences between maximum-likelihood
and Bayesian statistical approaches, with the former seeking the single most likely ex-
planation for the data, and the latter seeking to fully characterize model uncertainty.
Additionally, the BMDS method improves flexibility, allowing extensions to the basic car-
tographic model, such as the incorporation of virus avidities and evolutionary priors, that
improve fit and add biological interpretability.
Antigenic evolution across influenza lineages
Through our analysis, we reveal the antigenic, as well as evolutionary, relationships among
viruses in influenza A/H3N2, A/H1N1, B/Vic and B/Yam, quantifying both antigenic
and evolutionary distances between strains (Figure 2). Over the time period of 1968 to
2011, influenza A/H3N2 shows substantially more antigenic evolution than is exhibited
by A/H1N1 over the course of 1977 to 2009 or B/Vic and B/Yam over the course of
1986 to 2011. We observe prominent antigenic clusters in A/H3N2 and A/H1N1, but less
prominent, though still apparent, clustering in B/Vic and B/Yam. Antigenic clusters show
high genetic similarity, so that we observe very few mutation events leading to each cluster,
rather than the repeated emergence of clusters. This analysis makes the fate of antigenic
clusters obvious, with two clusters in A/H3N2 (Victoria/75 and Beijing/89) appearing to
be evolutionary dead-ends. Labeling of prominent antigenic clusters in figures 2 and 3
is intended as a rough guide for orientation and not as exhaustive catalog of antigenic
variation.
HI assays lack sensitivity beyond a certain point, so that for A/H3N2, cross-reactive mea-
surements only exist between strains sampled at most 14 years apart, leaving only thresh-
old titers, e.g. ‘<40’, in more temporally distant comparisons. Because of the threshold
of sensitivity of the HI assay, it’s difficult to distinguish a linear trajectory in 2D anti-
genic space from a slightly curved trajectory (see Materials and Methods). To solve this
problem of identifiability, we assumed a weak prior that favors linear movement in the
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Figure 2. Antigenic locations of A/H3N2, A/H1N1, B/Vic and B/Yam viruses show-
ing evolutionary relationships between virus samples. Circles represent a posterior sam-
ple of virus locations and have been shaded based on year of isolation. Antigenic units rep-
resent two-fold dilutions of the HI assay. Absolute positioning of lineages, e.g. A/H3N2 and
A/H1N1, is arbitrary. Lines represent mean posterior diffusion paths when virus locations are
fixed. Prominent antigenic clusters are labeled after vaccine strains present within clusters, and
are abbreviated from Hong Kong/68, England/72, Victoria/75, Bangkok/79, Sichuan/87, Bei-
jing/89, Beijing/92, Wuhan/95, Sydney/97, Fujian/02, California/04, Wisconsin/05, Brisbane/07,
Perth/09 (A/H3N2), USSR/77, Singapore/86, Beijing/95, New Caledonia/99, Solomon Islands/06
(H1N1), Victoria/87, Hong Kong/01, Malaysia/04, Brisbane/08 (Vic), Yamagata/88, Shanghai/02,
Florida/06, Wisconsin/10 (Yam).
2D antigenic space (present in models 6 through 9; Table 1), with the slope of the linear
relationship and the precision of the relationship incorporated into the Bayesian model
(see Materials and methods). Because of this, we interpret map locations locally rather
than globally, and assess rates of antigenic movement without making strong statements
about the larger configuration under which the movement occurs.
We find that influenza A/H3N2 evolved along antigenic dimension 1 at an estimated rate
of 1.01 antigenic units per year (Figure 3, Table 2). However, we observe occasional large
jumps in antigenic phenotype (Figure 3), corresponding to cluster transitions identified
by Smith et al. [7]. Most variation is contained within the first antigenic dimension, but
dimension 2 occasionally shows variation when two antigenically distinct lineages emerge
and transiently coexist (Figure 2), as is the case with the previously identified Beijing/89
and Beijing/92 clusters.
We find that other lineages of influenza evolved in antigenic phenotype substantially slower
than A/H3N2 (Figure 3, Table 2). Influenza A/H1N1 evolved at a rate of 0.62 units per
year, but showed a similar pattern of punctuated antigenic evolution with occasional larger
jumps in phenotype, such as the emergence of the Solomon Islands/06 cluster. Influenza
B/Victoria and B/Yamagata evolved slower still, with mean estimated rates 0.42 units
per year and 0.32 units per year, respectively. Punctuated evolution is less obvious in
B/Yam and B/Vic compared to A/H3N2 and A/H1N1, but antigenic clusters are still
apparent, with recent transitions to the Brisbane/08 cluster in B/Vic [15] and to the
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Figure 3. Antigenic drift of A/H3N2, A/H1N1, B/Vic and B/Yam viruses showing
evolutionary relationships between virus samples. Antigenic drift is shown in terms of
change of location in the first antigenic dimension through time. Circles represent a posterior sam-
ple of virus locations and have been shaded based on year of isolation. Antigenic units represent
two-fold dilutions of the HI assay. Relative positioning of lineages, e.g. A/H3N2 and A/H1N1, in
the vertical axis is arbitrary. Lines represent mean posterior diffusion paths when virus locations
are fixed. Prominent antigenic clusters are labeled after vaccine strains present within clusters,
and are abbreviated from Hong Kong/68, England/72, Victoria/75, Bangkok/79, Sichuan/87, Bei-
jing/89, Beijing/92, Wuhan/95, Sydney/97, Fujian/02, California/04, Wisconsin/05, Brisbane/07,
Perth/09 (A/H3N2), USSR/77, Singapore/86, Beijing/95, New Caledonia/99, Solomon Islands/06
(H1N1), Victoria/87, Hong Kong/01, Malaysia/04, Brisbane/08 (Vic), Yamagata/88, Shanghai/02,
Florida/06, Wisconsin/10 (Yam).
Wisconsin/10 cluster in B/Yam [16]. Interestingly, a minor lineage of B/Vic, denoted
B/Hubei-Songzi/51/2008 [15], has persisted through 2011, while remaining antigenically
distinct from B/Brisbane/60/2008 viruses (Figure 3). Although we observe significantly
different drift rates between lineages, we observe less variation in diffusion volatility (Ta-
ble 2). This is reflected in Figure 3, where all four lineages exhibit similar levels of standing
antigenic variation, despite A/H3N2 drifting more quickly in antigenic phenotype.
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Table 2. Estimates of drift rate µ (in units per year), diffusion volatility σ2x (in units
2
per year) and scaled effective population size Neτ (in years) for influenza A/H3N2,
A/H1N1, B/Vic and B/Yam including posterior means and 95% highest posterior
density intervals.
Lineage Drift µ Volatility σ2x Effective pop size Neτ
A/H3N2 1.01 (0.98–1.04) 1.25 (0.98–2.35) 5.03 (4.42–5.73)
A/H1N1 0.62 (0.56–0.67) 0.92 (0.65–1.56) 6.38 (4.99–8.12)
B/Vic 0.42 (0.32–0.51) 1.22 (0.85–2.25) 10.40 (8.42–12.80)
B/Yam 0.32 (0.25–0.39) 0.71 (0.46–1.36) 9.48 (7.76–11.50)
These patterns of antigenic drift influence the corresponding virus phylogenies (Figure 4).
Influenza A/H3N2 has a characteristically spindly tree showing rapid turnover of the
virus population, while A/H1N1 and B have trees that show greater degrees of viral
coexistance (Figure 4). The scaled effective population size Neτ measures the timescale
of coalescence of a phylogeny and quantifies the visual distinction between a ‘spindly’ tree
and a ‘bushy’ tree [17]. In this case, Ne represents the number of concurrent infections
in a panmictic population with generation interval τ (time separating infections up the
genealogical tree), so that Neτ is measured in terms of years and gives the expected waiting
time for two randomly chosen lineages to coalesce in the genealogical tree. We see that
Neτ broadly correlates with the rate of antigenic drift (Table 2), with A/H3N2 showing
fast drift and reduced effective population size as expected from basic epidemiological
models [18]. Antigenic drift results in the replacement of antigenically primitive lineages
by antigenically advanced lineages, thereby reducing genealogical diversity.
Thus, we observe a faster rate of antigenic drift in influenza A/H3N2 than in A/H1N1 or
either lineage of influenza B. Previous work using general epidemiological models has sug-
gested that rates of antigenic drift may be influenced by both the fundamental reproductive
number R0 and the rate at which mutation decreases cross-immunity [19,20]. Correspond-
ingly, models specific to influenza evolution ascribe differences in the rate of antigenic drift
of A/H3N2 relative to A/H1N1 and influenza B to either greater R0 or greater mutation
rate [18, 21]. Without more detailed epidemiological modeling, the present study cannot
conclusively distinguish between these causal possibilities.
Punctuated evolution and its epidemiological consequences
We sought to summarize year-to-year patterns of antigenic drift by calculating the dif-
ference in mean virus location between consecutive years (Figure 5A). We estimate year-
to-year antigenic drift for years 1992 to 2011 by calculating the average location along
dimension 1 of phylogenetic lineages present in the tree at year i and comparing this lo-
cation to the average location of phylogenetic lineages present in the tree at year i − 1.
There may often be large discontinuities in virus locations across the population; our use of
difference in mean location is meant to capture both the distance between antigenic clus-
ters and also the change in cluster frequency over consecutive years. We observe greater
heterogeneity in year-to-year antigenic drift in type A than in type B lineages (Figure 5B),
with standard deviation of year-to-year antigenic drift equal to 0.97 units in A/H3N2, 0.66
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Figure 4. Time-resolved phylogenetic trees of A/H3N2, A/H1N1, B/Vic and B/Yam
viruses. The maximium-clade credibility (MCC) tree is shown for each virus. These trees show
genealogical relationships, so that branches are measured in terms of years rather than substitu-
tions.
units in A/H1N1, 0.46 units in B/Vic and 0.26 units in B/Yam. This analysis classifies
drift only to the level of consecutive years; some coarse-graining of the timings of transition
events will necessarily occur.
We investigate the relationship between rates of antigenic drift and seasonal incidence in
the USA in A/H3N2, A/H1N1, B/Vic and B/Yam. We measure seasonal incidence from
USA CDC influenza surveillance reports for each virus lineage (A/H3N2, A/H1N1, B/Vic,
B/Yam) by taking the average influenza-like (ILI) percentage in a season and multiplying
this by the relative proportion of virus isolations attributable to a particular influenza
lineage in a season (see Materials and methods). This measure of incidence has previously
been shown to have have predictive power in the analysis of seasonal influenza trends [22].
We analyze incidence from the 1998/1999 to the 2008/2009 seasons to avoid possible
complications from the 2009 pandemic. We begin by comparing overall rates of antigenic
drift (Figure 3, Table 2) to overall levels of seasonal incidence across influenza lineages,
finding a significant correlation between rate of antigenic drift and relative incidence across
the four lineages (Pearson correlation, r = 0.97, p = 0.041).
We follow-up this analysis with a more detailed analysis of year-to-year variation in anti-
genic drift and lineage-specific incidence, comparing incidence in a season to antigenic
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Figure 5. Year-to-year antigenic drift between 1992 and 2011 in A/H3N2, A/H1N1,
B/Vic and B/Yam viruses. (A) Timeseries of year-to-year antigenic drift between 1992 and
2011 in A/H3N2, A/H1N1, B/Vic and B/Yam viruses. Colored lines represent year-to-year anti-
genic drift, where drift for year i is measured as the mean of antigenic dimension 1 of phylogenetic
lineages in year i compared to the mean of antigenic dimension 1 of phylogenetic lineages from
the previous year i− 1. For example, 2000 represents difference in antigenic dimension 1 between
viruses from 1999 and 2000. Error bars represent 50% Bayesian credible intervals of year-to-year
drift. Gray dotted lines represent lineage-specific seasonal incidence in the USA taken as average
influenza-like illness (ILI) multiplied by proportion of viruses attributable to a lineage for each
season. Here, 2000 represents the 2000/2001 influenza season. (B) Distribution of year-to-year
antigenic drift between 1992 and 2011 in A/H3N2, A/H1N1, B/Vic and B/Yam viruses.
drift of viruses coming into this season (Figure 5A). For example, we compare antigenic
drift of viruses from 2000 to 2001 to incidence in the 2001/2002 season. Within each
virus lineage, we find that years with pronounced antigenic drift tend to show increased
incidence (Figure 6), finding Pearson correlation coefficients of 0.51, 0.29, 0.44 and 0.14
for A/H3N2, A/H1N1, B/Vic and B/Yam respectively. We calculated significance using
bootstrap permutation tests finding p-values of 0.056, 0.201, 0.097 and 0.341 respectively.
We applied a similar bootstrap permutation test to calculate the significance of finding the
observed degree of correlation across all four lineages, arriving at a p-value of 0.018. The
fact that we observe periods of pronounced antigenic drift preceding increased incidence
in each of the four influenza lineages suggests a causal relationship, in which antigenic
evolution drives increased incidence.
However, it is possible that if sampling count influences cartographic estimates then a
spurious correlation could arise in which years with greater incidence have higher sample
11
Figure 6. Relationship between antigenic drift and seasonal incidence for years 1998
to 2009 in influenza A/H3N2, A/H1N1, B/Vic and B/Yam. Antigenic drift from year
i− 1 to year i is compared to incidence in the season i / i+ 1. For example, year-to-year antigenic
drift from 2000 to 2001 is measured against incidence in the 2001/2002 season.
counts and artifactually high estimates of drift. We controlled for this possibility by
testing to see if viral isolate count influences estimates of year-to-year drift by correlating
drift between years i and i − 1 against the ratio of the number of isolates from year i
to the number of isolates from year i − 1. We found little correlation when combining
data across lineages (Figure 7, Pearson’s r = −0.01). We tested significance following the
same bootstrap procedure we used to assess the correlation between drift and incidence,
finding a p-value of 0.514. Separating lineages gave p-values of 0.717, 0.246, 0.337, 0.504
for A/H3N2, A/H1N1, B/Vic and B/Yam, respectively. These findings suggest our results
to be unbiased with regard to sample count.
Figure 7. Relationship between antigenic drift and sample counts for years 1998 to
2011 in influenza A/H3N2, A/H1N1, B/Vic and B/Yam. Antigenic drift from year i−1 to
year i is compared to the ratio of sample counts in year i to counts in year i−1. Only comparisons
which had one or more samples in years i− 1 and i were retained, leaving 11 A/H3N2, 7 A/H1N1,
9 B/Vic and 10 B/Yam comparisons. Points are colored according to influenza lineage based on
the color scheme in Figure 6.
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Conclusions
Understanding antigenic evolution in seasonal influenza is crucial to our efforts of surveil-
lance and control. Cartographic methods allow complex HI datasets to be compressed
to more approachable location-based summaries that quantify antigenic relationships be-
tween strains, including relationships not directly measured via HI. In this study we pro-
vide a foundation for evolutionary antigenic cartography, which seeks to simultaneously
assess antigenic phenotype and antigenic evolution. We use this approach to characterize
competitive dynamics across influenza lineages A/H3N2, A/H1N1, B/Vic and B/Yam and
show that antigenic evolution within each lineage drives strain replacement and contributes
to seasonal incidence patterns. We find that influenza A/H3N2 evolves faster in antigenic
phenotype than A/H1N1, which in turn evolves faster than B/Vic or B/Yam. Conse-
quently, the influenza A/H3N2 virus population turns over more quickly than A/H1N1 or
influenza B, exhibiting a smaller effective population size and a ‘spindlier’ phylogenetic
tree. Furthermore, we observe a correlation between antigenic drift and viral incidence
both across and within influenza lineages. The finding that antigenic evolution correlates
with subsequent increased incidence within a lineage suggests a causal role for antigenic
drift driving influenza incidence patterns. The correlation between incidence and drift
further suggests the possibility of using HI data at the start of an influenza season to
predict which lineage will subsequently predominate.
The statistical framework presented here represents a baseline to which further advance-
ments in modeling antigenic phenotype and evolution may be made. For example, our
likelihood-based model facilitates the inclusion of possible covariates affecting immunolog-
ical titer, which could include experimental factors such as red blood cell type used in the
HI assay [23] and whether oseltamivir is included in the HI reaction [24]. Additionally, this
framework should be ideally suited to uncovering genetic determinants of antigenic change,
as both the sequence state and antigenic location of internal nodes in the phylogeny may
be estimated. In this fashion, it should be possible to correlate sequence substitutions
directly to antigenic diffusion. Identifying viruses that will come to predominate in the
global virus population while they are still at low frequency remains an enormous chal-
lenge. However, combining evolutionary and antigenic information may eventually prove
useful in identifying low-frequency, but expanding, lineages of antigenically novel viruses
that represent ideal targets for vaccine strain selection.
Materials and methods
Antigenic cartography
Antigenic characteristics of viral strains are often assessed through immunological assays
such as the hemagglutination inhibition (HI) assay [6]. At heart, these assays compare
the reactivity of one virus strain to antibodies raised against another virus strain via
challenge or vaccination. In the case of HI, the measurement of cross-reactivity takes the
form of a titer representing the dilution factor at which serum raised against a particular
virus ceases to be effective at inhibiting the binding of another virus to red blood cells.
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These factors are commonly assessed by serial dilution, so that HI titers will form a log
series, 40, 80, 160, etc . . . . Because experimental HI titers typically differ by factors of
two, we find it convenient to work in log2 space and represent the titer of virus i against
serum j as Hij = log2(HI titer), i.e. a titer of 160 has Hij = 7.32. Due to experimental
constraints, most comparisons cannot be made, leading to a sparse observation matrix
H = {Hij}. Further, measurements are usually interval and truncated, e.g. inhibition
may cease somewhere between the serial titers of 160 and 320, or inhibition may be absent
at all titers assayed, suggesting a threshold somewhere between 0 and 40.
Previous work [7,25] has used multidimensional scaling (MDS) to place viruses and sera on
an ‘antigenic map’. These methods heuristically optimize locations of viruses and sera by
seeking to minimize the sum of squared errors between titers predicted by map locations
and observed titers. Antigenic maps produced by these methods have proven useful in
categorizing virus phenotypes [7], but the extension of these methods to integrate genetic
data remains notably lacking.
Here, we follow previous models in representing antigenic locations as points in a low P -
dimensional antigenic map. One of our initial goals is to find an optimal projection of the
high-dimensional distance matrix H into this lower dimensional space. We conduct this
projection using Bayesian multidimensional scaling (BMDS) [26] in which we construct a
probabilistic model to quantify the fit of a particular configuration of cartographic locations
to the observed matrix of serological measurements. Typically, P = 2, but higher or lower
dimensions may better reflect the data.
Let xi ∈ RP represent the cartographic location of virus i for i = 1, . . . , n, so that xi =
(xi1, xi2)
′ for P = 2. Similarly, let yj represent the cartographic location of serum j
for j = 1, . . . , k, so that yj = (yj1, yj2)
′ for P = 2. For notational compactness, we
collect together all virus coordinates into an n×P matrix X = (x1, . . . ,xn)′ and all serum
coordinates into an k×P matrix Y = (y1, . . . ,yk)′. Virus and serum may be isolated from
/ raised against the same strain and have different cartographic locations, and separate
serum isolates raised against the same strain may also have different cartographic locations.
This gives a set of distances between virus and serum cartographic locations
δij = ||xi − yj ||2, (1)
where || · ||2 is an L2 norm.
Traditional approaches to antigenic cartography [7] begin by defining immunological dis-
tance as
dij = sj −Hij , (2)
whereHij is the log2 titer of virus i against serum j and serum potency sj = max(H1j , . . . ,Hnj)
is fixed. In following multidimensional scaling, these approaches attempt to optimize over
unknown X and Y such that ∑
(i,j)∈I
(δij − dij)2 (3)
is minimized, where I = {(i, j) : Hij is measured}. In the case of threshold measurements,
this error function is modified slightly; see [7] for further details.
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Here, we instead assume a probabilistic interpretation in which an observed titer is nor-
mally distributed around its cartographic expectation with variance ϕ2,
Hij ∼ N (sj − δij , ϕ2). (4)
Consequently, the likelihood of observing an exact titer given the placement of antigenic
locations is
f|(Hij) = φ
(
Hij + δij − sj
ϕ
)
, (5)
where φ(·) represents the standard normal probability density function (PDF). Previous
BMDS has employed a sampling density truncated to strictly positive quantities since
dij are directly observed, non-negative quantities. In the antigenic setting, these remain
random and can be negative since neither sj is known nor is Hij observed with much
precision.
HI assays sometimes show no inhibition at all measured titrations, e.g. a measurement can
be reported as ‘<40’. In this case, the likelihood of observing the threshold measurement
follows the cumulative density of the lower tail of the normal distribution
fy(Hij) = Φ
(
Hij + δij − sj
ϕ
)
, (6)
where Φ(·) represents the standard normal cumulative distribution function (CDF). Al-
though it is simplest to assume that immunological measurements represent point esti-
mates, it seems more natural to assume that the threshold for inhibition occurs between
two titers, e.g. we observe inhibition at 1:160 dilution and no inhibition at 1:320 dilution.
Rather than taking the HI titer as 160, we can instead treat this as an interval measure-
ment, assuming that the exact titer for inhibition would occur somewhere between 160
and 320. HI titers are usually reported as the highest titer that successfully inhibits virus
binding, so that in this case, we calculate the likelihood of an interval measurement as
funionsq(Hij) = Φ
(
Hij + δij − sj + 1
ϕ
)
− Φ
(
Hij + δij − sj
ϕ
)
. (7)
These likelihoods are illustrated in Figure 8. Throughout our analyses, we use interval
likelihoods funionsq rather than point likelihoods f| unless otherwise noted.
We calculate the overall likelihood by multiplying probabilities of individual measurements
L(X,Y) =
∏
(i,j)∈I
f(Hij), (8)
using probability functions f|, fy and funionsq as appropriate. We begin by assuming indepen-
dent, diffuse normal priors on virus and serum locations
xi ∼ N (m,Σ)
yj ∼ N (m,Σ), (9)
where m = (0, . . . , 0)′ and Σ is a diagonal matrix with diagonal elements all equal to
10000.
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Figure 8. Likelihood of HI titers in the BMDS model. Here we show the likelihoods
of observing three different outcomes given δij = 4, ϕ = 0.95 and sj = log2(1280) = 10.32.
The likelihood of observing a threshold titer of ‘<40’ is equal to the lower tail of the probability
density function fy(5.32) = 0.146. The likelihood of observing a point measurement with an exact
inhibiting titer of ‘90.5’ is equal to the density function f|(6.5) = 0.413. The likelihood of observing
an interval measurement with an inhibiting titer somewhere between ‘160’ and ‘320’ is equal to
funionsq(7.32) = 0.129.
Virus avidity and serum potency
The preceding model represents immunological distance as a drop in titer against the most
reactive comparison for a particular serum. However, this model may be biased in some
circumstances. In one example, if a particular serum j is only measured against distant
viruses, its maximum titer will be artificially low and the likelihoods concerning this serum
will appear poor. To address this issue, we relax the assumption of fixed sj values and treat
the expected log2 titer when δij = 0 as a random variable. In this case, Hij still follows
equation 4 with expectation sj − δij , but the vector of ‘serum potencies’ s = (s1, . . . , sk)
is random and estimated rather than fixed. We assume that sj values are hierarchically
distributed according to a normal distribution. We take an Empirical Bayesian approach
in specifying the mean and variance of this distribution, set to the empirical mean and
empirical variance of the set of maximum titers across sera {max(H1j , . . . ,Hnj) : j =
1, . . . , k}. This formulation assumes that particular sera are more reactive in general than
other sera.
Additionally, we follow the same logic and assume that some virus isolates are more
reactive than other virus isolates and include a parameter for ‘virus avidity’ vi representing
the general level of reactivity across HI assays. With virus avidity included, observed titers
follow
Hij ∼ N
(
vi + sj
2
− δij , ϕ2
)
, (10)
and the vector of virus avidities vi for i = 1, . . . , n is estimated in an analogous hierarchical
fashion, with v normally distributed with mean and variance equal to the empirical mean
and variance of the set of maximum titers across viruses {max(Hi1, . . . ,Hik) : i = 1, . . . , n}.
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Figure 9. Schematic antigenic map with three viruses and two sera. (A) Map with
virus 1 and virus 3 antigenically similar. (B) Map with virus 1 and virus 3 antigenically divergent.
Virus 1 is shown in blue, virus 2 is shown in red and virus 3 is shown in yellow. Virus isolates are
represented by filled circles, sera raised against viruses are shown as open circles and map distances
δij are shown as solid lines connecting viruses and sera. Sera from virus 1 is compared against
viruses 1 and 2, while sera from virus 2 is compared against viruses 2 and 3. Configurations (A)
and (B) represent cartographic models that would give equal likelihoods to a set of serological data
{H11, H21, H22, H32}.
Drift model of antigenic evolution
As presented, multiple configurations of virus and serum locations X and Y will give the
same likelihood of an observed data matrix H. An example of this phenomenon is shown
in Figure 9. In this case, it is impossible to determine from the HI data at hand whether
the blue and yellow viruses are antigenically similar (Figure 9A) or antigenically divergent
(Figure 9B). This presents an issue of model identifiability, where absolute, as opposed
to relative, antigenic locations cannot be determined from observing the serological data
alone. Thus, in order to achieve more a interpretable model we impose a weak prior on
global locations. In influenza, it’s clear that antigenic distance between strains increases
with time [7, 25]. To capture this, we replace our previous diffuse prior with an informed
prior in which the expected location of viruses and sera increases with date of sampling
along dimension one, and each virus and serum location follows an independent normal
distribution centered around this temporal expectation, so that
xi1 ∼ µ ti +N (0, σ2x)
yj1 ∼ µ tj +N (0, σ2y), (11)
where t is the difference between the date of the indexed virus or serum and the date
of the earliest sampled virus or serum, and other dimensions follow xim ∼ N (0, σ2x) and
yjm ∼ N (0, σ2y) for m ≥ 2. Thus, this model assumes that virus and serum locations drift
in a line across the antigenic map at rate µ. The parameter σx determines the breadth of
the cloud of virus locations at each point in time, while σy determines the breadth of the
cloud of serum locations.
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Phylogenetic diffusion model of antigenic evolution
We simultaneously model antigenic locations and genetic relatedness by assuming that
virus locations are influenced by evolution following a Brownian motion process [12]. To
do this, we replace the previous prior specifying independent virus locations with a prior
that incorporates covariance based on shared evolutionary history
X ∼
µ t1 0... ...
µ tn 0
+ Evolutionary Brownian Process(σx, τ) (12)
for P = 2, where σx is the volatility parameter of the Brownian motion over virus locations
and τ is a phylogeny specifying tree topology and branch lengths. Thus, viruses which are
genetically similar are induced to have prior locations close to one another on the antigenic
map. In the evolutionary Brownian process, the tips of the phylogeny τ correspond to the
set of virus locations (x1, . . . ,xn), and the probability of observing tip locations depends
on the locations of internal nodes (xn+1, . . . ,x2n−2) and on the location of the root node
x2n−1. This process assumes that a virus location xi follows from the location of its parent
virus xf(i), and with the addition of drift along dimension 1, is distributed as
xi ∼ (µdi, 0)′ +N (xf(i), di Σ) (13)
for P = 2, where f(i) is a function that maps nodes to parental nodes, di is the length
of the branch connecting virus i to parent virus f(i), and Σ is a diagonal matrix with
diagonal elements all equal to σ2x. The root virus location x2n−1 is assumed to follow a
normal distribution with expectation (µ t2n−1, 0)′ for P = 2 and variance determined by the
diffusion volatility σx [12]. The probability of virus locations p(X|µ, σx, τ) is determined
through analytical integration across internal states following the methods introduced
in [12]. This formulation corresponds to a Wiener process with drift, in which the drift
term µ only influences the expected states of nodes along the phylogeny, but does not
influence the covariance structure among these nodes, which remains the same as it does
in a standard Wiener process [27]. This allows the separation in equation 12 between drift
terms affecting only expectations and the evolutionary Brownian process that includes
covariance among virus locations x1, . . . ,xn.
Here, the phylogenetic tree τ is estimated using sequence data for viruses 1, . . . , n according
to well established methods implemented in the software package BEAST [28].
Posterior inference
Top-level priors for 1/ϕ2, µ, 1/σ2x, and 1/σ
2
y are assumed to follow diffuse Gamma(a, b)
distributions with a = 0.001 and b = 0.001. These diffuse priors were chosen to be non-
informative and provide little-to-no weight on the resulting posterior distributions. Under
the full model, the posterior probability of observing virus and serum locations given
immunological data is factored
p(X,Y|H) ∝ p(H|X,Y, s,v, ϕ) p(X|µ, σx, τ) p(Y|µ, σy) p(s,v, ϕ, µ, σx, σy, τ). (14)
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We sample from this posterior distribution using the MCMC procedures implemented
in the software package BEAST [28]. Metropolis-Hastings proposals include transition
kernels that translate individual virus and serum locations xi and yj and individual virus
avidities vi and serum potencies sj , and other transition kernels that scale the entire
set of virus and serum locations X and Y and that scale parameters ϕ, µ, σx and σy.
For the present analysis, a two-step approach was taken to sample phylogenies, where
a posterior sample of phylogenies was gathered using sequence data and then, in the
cartographic analysis, trees from this set were randomly proposed and accepted following
the Metropolis-Hastings algorithm [29].
Genetic, antigenic and surveillance data
We compiled an antigenic dataset of hemagglutination inhibition (HI) measurements of
virus isolates against post-infection ferret sera for influenza A/H3N2 by collecting data
from previous publications [7, 10, 11, 15], NIMR vaccine strain selection reports for 2002
and 2008–2012 [30–36] and the Feb 2011 VRBPAC report [37]. We queried the Influenza
Research Database [38] and the EpiFlu Database [39] for HA nucleotide sequences by
matching strain names, e.g. A/HongKong/1/1968, and only strains for which sequence was
present was retained. If a strain had multiple sequences in the databases we preferentially
kept the IRD sequence and preferentially kept the longest sequence in IRD. Many strains
had full length HA sequences, while other strains only possessed HA1 sequences. Sequences
were aligned using MUSCLE v3.7 under default parameters [40]. This dataset had 2051
influenza isolates (present as either virus or serum in HI comparisons) dating from 1968
to 2011. However, the majority of isolates were present from 2002 to 2007. Because
we are interested in longer-term antigenic evolution, we subsampled the data to have at
most 20 virus isolates per year, preferentially keeping those isolates with more antigenic
comparisons. We then kept only those serum isolates that are relatively informative to
the antigenic placement of viruses, dropping serum isolates that are compared to 4 or
fewer different virus isolates. This censoring left 402 virus isolates, 519 serum isolates and
10,059 HI measurements. Each virus isolate was compared to an average of 21.9 serum
isolates, and each serum isolate was compared to an average of 18.0 virus isolates.
Antigenic data for influenza A/H1N1 was collected from previous publications [10,15,41–
54] and NIMR vaccine strain selection reports for 2002–2010 [30–33, 55–63]. The same
procedure that was followed for A/H3N2 was repeated to match sequence data and to
subsample antigenic comparisons. This procedure yielded 115 virus isolates, 77 serum
isolates and 1882 HI measurements over the course of 1977 to 2009. Each virus isolate
was compared to an average of 10.0 serum isolates, and each serum isolate was compared
to an average of 16.2 virus isolates.
Antigenic comparisons for influenza B/Victoria were collated from previous publications
[3,10,64–71] and vaccine strain selection reports for 2002–2012 [30–36,55–62,72–74]. Here,
the sequence matching and subsampling procedure yielded 179 virus isolates, 70 serum
isolates and 2003 HI measurements over the course of 1986 to 2011. Each virus isolate
was compared to an average of 6.5 serum isolates, and each serum isolate was compared
to an average of 16.7 virus isolates.
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Antigenic comparisons for influenza B/Yamagata were collected from previous publications
[3,10,64–71,75–81] and vaccine strain selection reports for 2002–2012 [30–36,55–62,72–74].
For B/Yamagata, the matching and subsampling procedure resulted in 174 virus isolates,
69 serum isolates and 1962 HI measurements over the course of 1987 to 2011. Each virus
isolate was compared to an average of 6.9 serum isolates, and each serum isolate was
compared to an average of 17.3 virus isolates.
Surveillance data was obtained from the Centers of Disease Control and Prevention Flu-
View Influenza Reports from the yearly summaries of influenza seasons 1997–1998 to
2010–2011 [82]. As an example, one report states “collaborating laboratories in the United
States tested 195,744 respiratory specimens for influenza viruses, 27,682 (14%) of which
were positive. Of these, 18,175 (66%) were positive for influenza A viruses, and 9,507
(34%) were positive for influenza B viruses. Of the 18,175 specimens positive for influenza
A viruses, 7,631 (42%) were subtyped; 6,762 (87%) of these were seasonal influenza A
(H1N1) viruses, and 869 (13%) were influenza A (H3N2) viruses.” In this case, we esti-
mate the relative proportion of A/H3N2 of the four lineages as 0.66×0.13 = 0.09. Similar
calculations were performed for A/H1N1, B/Vic and B/Yam.
Implementation
Phylogenetic trees were estimated for A/H3N2, A/H1N1, B/Vic and B/Yam using BEAST
[28] and incorporated the SRD06 nucleotide substitution model [83], a coalescent demo-
graphic model with constant effective population size and a strict molecular clock across
branches. MCMC was run for 60 million steps and trees were sampled every 50,000 steps
after allowing a burn-in of 10 million steps, yielding a total sample of 2000 trees. These
trees were treated as a discrete set of possibilities when subsequently sampled in the
BMDS analysis [29]. However, it would be possible to jointly sample from sequence data
and serological data using these methods.
MCMC was used to sample virus locations X, serum locations Y, virus avidities v, serum
potencies s, MDS precision 1/ϕ2, antigenic drift rate µ, virus location precision 1/σ2x,
serum location precision 1/σ2y and phylogenetic tree τ . MCMC chains were run for 500
million steps and parameter values sampled every 200,000 steps after a burn-in of 100
million steps, yielding a total of 2000 MCMC samples. In all cases when drift parameter
µ was included the MCMC chain mixed well and arrived at the same estimated posterior
distribution from different starting points. However, without drift parameter µ, maps for
A/H3N2 showed some degree of metastability, where some chains would converge on one
solution and other chains would converge on a different solution. We favor models that
include µ, because its inclusion, in addition to correcting most identifiability issues, yields
much improved mixing of antigenic locations.
There is some difficulty summarizing posterior cartographic samples, as sampled virus and
serum locations represent only relative quantities, and because of this, over the course of
the MCMC, virus locations may shift. Our prior on virus and serum locations removes
much of this issue, orienting the antigenic map along dimension 1 and fixing it to begin at
the origin. However, local isometries are often still a problem. For example, in A/H3N2 the
HK/68, EN/72 and VI/75 clusters may rotate in relation to other clusters. Consequently, it
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may be difficult to fully align MCMC samples using Procrustes analysis. For the present
study, we take a simple approach and sample a single MCMC step and visualize the
antigenic locations at this state (Figures 2, Figure 3). Then, for specific quantities of
interest, like rate of antigenic drift and rate of diffusion at different points along the
phylogeny, we calculate the quantity across MCMC samples to yield an expectation and a
credible interval. This approach accurately characterizes uncertainty that may be hidden
in an analysis of a single antigenic map.
We summarize diffusion paths of viral lineages (Figure 2, Figure 3) by taking each virus
and reconstructing x and y locations along antigenic dimensions 1 and 2 backward through
time. We use MCMC to sample tip locations, but when outputting trees sample internal
node locations using a peeling algorithm as described in [84]. Thus, after the MCMC is
finished we have a posterior sample of 2000 trees each tagged with estimated tip locations
and internal node locations. We post-processed each posterior tree by conducting a linear
interpolation between parent-child node locations to arrive at x and y values at intervals
of 0.05 years for each virus. Then, for each interval, x and y values are averaged across
the sample of posterior trees. We draw lines between these locations to approximate mean
posterior diffusion paths. As virus lineages coalesce backwards through time down the
phylogeny these diffusion paths will also coalesce.
Comparison with previous results
Here, we attempt to compare antigenic locations inferred by our BMDS model to antigenic
locations previously inferred by the error minimization methods of Smith et al. [7], referred
to here as antigenic cartography by MDS. For this comparison, we use exactly the same HI
data used to produce the results in [7], consisting of 273 virus isolates, 79 serum isolates
and a total of 4252 HI measurements taken between 1968 and 2003. We begin with a
BMDS analog of the antigenic model used in [7], where serum potencies are taken as
the maximum titer of a particular ferret serum and the expected log2 drop in HI titer is
proportional to Euclidean distance between virus and serum locations. To bring models
into further alignment, we use a Uniform(−100, 100) distribution over virus locations and
serum locations. Unsurprisingly, we find that this BMDS model produces results that are
strongly congruent with MDS results (Figure 10). Antigenic cluster locations are consistent
between methods (Figure 10A–B) and antigenic distances between pairs of viruses are
consistent between temporally similar and temporally divergent viruses (Figure 10C–E),
suggesting that the resulting maps are consistent at both local and global scales. Credible
intervals of antigenic distances for the BMDS model remain narrow across the temporal
spectrum (Figure 10C–E), implying a fair degree of rigidity to the map.
Smith et al. [7] show that there exist at least two solutions in their assignment of antigenic
locations, involving the rotation of clusters HK/68, EN/72 and VI/75 (shown in Figure
S2 of [7]). We observe the same metastable behavior in our analysis; some MCMC chains
converge on the solution shown in Figure 10B, while other MCMC chains converge on
the alternative solution shown in Figure 11B. The distribution of likelihood values appear
highly similar between these two solutions, suggesting that they represent global optima.
The rotation of the HK/68, EN/72 and VI/75 clusters creates a map that bends slightly,
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Figure 10. Comparison of A/H3N2 antigenic locations estimated by Smith et al. [7]
using MDS and an equivalent BMDS model. (A) MDS antigenic locations, reoriented so
that the primary dimension lies on the x-axis rather than on the y-axis as in Figure 1 of [7]. (B) A
posterior sample of antigenic locations from an equivalent BMDS model. In (A) and (B), viruses
are shown as colored circles, with color denoting antigenic cluster inferred by [7], and sera are
shown as gray points. (C) Antigenic distances between A/Bilthoven/16190/1968 and all other
viruses determined for both methods. (D) Antigenic distances between A/Fujian/411/2002 and all
other viruses determined for both methods. (E) Antigenic distances between 750 random pairs of
viruses determined for both methods. In (C), (D) and (E) red points show distances for the MDS
model and gray bars show the 95% credible interval of distances for the BMDS model, while the
red dashed line shows a LOESS regression to MDS distances, and the black dashed line shows a
LOESS regression to the BMDS distances. The BMDS model has a Uniform(−100, 100) prior on
antigenic locations and serum potencies fixed at maximum titer values.
so that temporally distant viruses appear closer in the rotated solution than in the original
solution (Figure 11C–E). In this case, it is clear that the solutions are locally consistent
between viruses up to ∼15 years divergent, even if there some degree of global flexibility.
As discussed in the main text, the presence of multiple optima with different degrees
of 2D curvature implies an issue of identifiability; the HI likelihood model alone cannot
distinguish between these possibilities. Because of this issue, and to more easily estimate
rates of antigenic drift, we include a model of systematic drift in antigenic location that
favors linear movement in the antigenic map. We find that including this drift prior on
antigenic locations removes the problem of identifiability. Antigenic locations produced by
this model remain locally consistent with MDS results between viruses∼15 years divergent,
but global comparisons show that this BMDS model has partitioned more variance to the
first antigenic dimension (Figure 12). We additionally find that including the drift prior
on antigenic locations often results in greater predictive power, with a slight improvement
of test error for the A/H1N1, B/Vic and B/Yam datasets (Table 1).
Our final BMDS model (model 9, Table 1) differs from antigenic model used by Smith et
al. [7] in including temporally- and phylogenetically-informed priors on antigenic locations
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Figure 11. Comparison of A/H3N2 antigenic locations estimated by Smith et al. [7]
using MDS and an equivalent BMDS model under an alternative solution. (A) MDS
antigenic locations, reoriented so that the primary dimension lies on the x-axis rather than on the
y-axis as in Figure 1 of [7]. (B) A posterior sample of antigenic locations from an equivalent BMDS
model that has converged on the alternative solution. In (A) and (B), viruses are shown as colored
circles, with color denoting antigenic cluster inferred by [7], and sera are shown as gray points. (C)
Antigenic distances between A/Bilthoven/16190/1968 and all other viruses determined for both
methods. (D) Antigenic distances between A/Fujian/411/2002 and all other viruses determined
for both methods. (E) Antigenic distances between 750 random pairs of viruses determined for
both methods. In (C), (D) and (E) red points show distances for the MDS model and gray bars
show the 95% credible interval of distances for the BMDS model, while the red dashed line shows
a LOESS regression to MDS distances, and the black dashed line shows a LOESS regression to the
BMDS distances. The BMDS model has a Uniform(−100, 100) prior on antigenic locations and
serum potencies fixed at maximum titer values.
and also in estimating serum and virus avidities. Here, we investigate the impact on anti-
genic locations of estimating virus avidity and serum potency in the BMDS model. To
isolate this difference, we use a Uniform(−100, 100) prior on antigenic locations. Surpris-
ingly, estimating virus avidity and serum potency results in a more linear antigenic map
(Figure 13), resembling the appearance of the map incorporating the antigenic drift prior,
while preserving local consistency. We generally observe congruence between MDS and
BMDS antigenic locations for viruses less than ∼10 years divergent (Figure 13E). How-
ever, specific viruses may be affected, for instance A/Bilthoven/16190/1968 (Figure 13C),
which appears more distant from all other viruses when serum and virus avidities are
included.
In this dataset, viruses 15 or more years divergent always yield threshold titers, and hence,
their relative locations must be indirectly inferred rather than through direct comparison.
This may explain why we observe local consistency between models at scales less than
∼15 years, but some degree of global inconsistency. Still, these results suggest that, when
making local comparisons, such as those used to calculate year-to-year antigenic drift
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Figure 12. Comparison of A/H3N2 antigenic locations estimated by Smith et al. [7]
using MDS and an extended BMDS model that includes date-informed priors on
antigenic locations. (A) MDS antigenic locations, reoriented so that the primary dimension lies
on the x-axis rather than on the y-axis as in Figure 1 of [7]. (B) A posterior sample of antigenic
locations from a BMDS model that includes date-informed priors on antigenic locations. In (A) and
(B), viruses are shown as colored circles, with color denoting antigenic cluster inferred by [7], and
sera are shown as gray points. (C) Antigenic distances between A/Bilthoven/16190/1968 and all
other viruses determined for both methods. (D) Antigenic distances between A/Fujian/411/2002
and all other viruses determined for both methods. (E) Antigenic distances between 750 random
pairs of viruses determined for both methods. In (C), (D) and (E) red points show distances for
the MDS model and gray bars show the 95% credible interval of distances for the BMDS model,
while the red dashed line shows a LOESS regression to MDS distances, and the black dashed line
shows a LOESS regression to the BMDS distances. The BMDS model has a date-informed prior
on antigenic locations and serum potencies fixed at maximum titer values.
(Figure 3), outcomes are expected to be robust to many model particulars.
Availability
Source code implementing the cartographic models has been made fully available as part
of the software package BEAST [28], and can be downloaded from its Google code reposi-
tory (http://code.google.com/p/beast-mcmc/). More details on implementing these mod-
els can be found at https://github.com/trvrb/flux/tree/master/example-xmls. Incidence
data and HI data used in this analysis is archived with Dryad (doi:10.5061/dryad.rc515).
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Figure 13. Comparison of A/H3N2 antigenic locations estimated by Smith et al. [7]
using MDS and an extended BMDS model that estimates serum and virus avidities.
(A) MDS antigenic locations, reoriented so that the primary dimension lies on the x-axis rather
than on the y-axis as in Figure 1 of [7]. (B) A posterior sample of antigenic locations from a BMDS
model that estimates virus avidity and serum potency. In (A) and (B), viruses are shown as colored
circles, with color denoting antigenic cluster inferred by [7], and sera are shown as gray points. (C)
Antigenic distances between A/Bilthoven/16190/1968 and all other viruses determined for both
methods. (D) Antigenic distances between A/Fujian/411/2002 and all other viruses determined
for both methods. (E) Antigenic distances between 750 random pairs of viruses determined for
both methods. In (C), (D) and (E) red points show distances for the MDS model and gray bars
show the 95% credible interval of distances for the BMDS model, while the red dashed line shows
a LOESS regression to MDS distances, and the black dashed line shows a LOESS regression to the
BMDS distances. The BMDS model has a Uniform(−100, 100) prior on antigenic locations and
virus avidities and serum potencies estimated in a hierarchical Bayesian fashion.
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